182 results on '"Extra, J. M."'
Search Results
2. Breast Cancer Patients’ Views on the Use of Genomic Testing to Guide Decisions about Their Postoperative Chemotherapy
3. Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation
4. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
5. Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study
6. De la pratique des coupes larges en anatomie pathologique après mammectomie partielle pour adénocarcinome invasif, à la réduction du taux de récidive locale
7. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients
8. Tailored chemotherapy based on tumour gene expression analysis: breast cancer patientsʼ misinterpretations and positive attitudes
9. Erratum: Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation
10. Reduced-intensity allogeneic transplantation for breast cancer
11. A Review of the Antitumour Activity of Vinorelbine in Breast Cancer
12. Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) inplatinum + taxanes sensitive advanced ovarian cancer (AOC) patients: Final results: 5023
13. PHASE II TRIAL OF OXALIPLATIN AND PACLITAXEL COMBINATION IN ADVANCED OVARIAN CANCER PATIENTS PRETREATED WITH CISPLATIN OR CARBOPLATIN ± TAXANES: PRELIMINARY RESULTS: 891
14. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients
15. Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer
16. Abstract P2-10-02: AVASTEM – Stem cells inhibition by bevacizumab in combination with neoadjuvant chemotherapy for locally advanced breast cancers: A prospective proof of concept randomized phase II trial
17. Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer
18. Treatment of Adult Acute Lymphoblastic Leukemia. Preliminary Results of a Trial from the French Group
19. Untreated hormone receptor positive/HER2-negative metastatic breast cancer survival with front-line chemotherapy and maintenance endocrine therapy
20. Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study
21. High-dose chemotherapy for inflammatory breast cancer: impact of immunohistochemical status on survival outcome
22. Abstract P4-13-23: Next-generation sequencing (NGS), array comparative genomic hybridization (aCGH) and patient-derived tumor xenograft (PDX) for precision medicine in advanced breast cancer: A single-center prospective study
23. Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study
24. 270P - Untreated hormone receptor positive/HER2-negative metastatic breast cancer survival with front-line chemotherapy and maintenance endocrine therapy
25. Treatment of Adult Acute Lymphoblastic Leukemia. Preliminary Results of a Trial from the French Group
26. Prise en charge des cancers du sein métastatique HER2 surexprimé
27. 297P - High-dose chemotherapy for inflammatory breast cancer: impact of immunohistochemical status on survival outcome
28. 274P - Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study
29. Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
30. Abstract OT2-3-05: AVASTEM: a phase II randomized trial evaluating anti-cancer stem cell activity of pre-operative bevacizumab and chemotherapy in breast cancer
31. Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes
32. Facteurs de risque et prescription de chimiothérapie dans les cancers du sein non métastatique
33. Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy
34. Surgical restaging of advanced Hodgkin's disease after first line chemotherapy
35. HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors
36. Serum proteomic prediction of progression-free survival in HER2-negative metastatic breast cancer patients receiving docetaxel as first-line treatment
37. Circulating tumor cells (CTCs) detection in a randomized phase II trial of neoadjuvant chemotherapy for large operable and locally advanced breast cancer (REMAGUS 02): Preliminary results
38. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer
39. Anthracyclines vs taxanes plus trastuzumab in HER2-positive metastatic breast cancer (MBC): A cross trial comparison of pivotal studies
40. Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) inplatinum + taxanes sensitive advanced ovarian cancer (AOC) patients: Final results
41. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+≤3) breast cancer (BC) patients (pts): First analysis of toxicity
42. 672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer
43. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
44. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer
45. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study.
46. Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus.
47. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
48. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method.
49. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials
50. A small GTP-binding protein is frequently overexpressed in peripheral blood mononuclear cells from patients with solid tumours
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.